289656-45-7 | 2,2-Bis(4-fluorophenyl)-2-phenylacetamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$16.00	$11.00
5mg	98%	in stock	$35.00	$24.00
50mg	98%	in stock	$42.00	$29.00
100mg	98%	in stock	$74.00	$52.00
500mg	98%	in stock	$313.00	$219.00
1g	98%	in stock	$548.00	$384.00
10g	98%	in stock	$4,910.00	$3,437.00

Description

• Catalog Number: AB33312
• Chemical Name: 2,2-Bis(4-fluorophenyl)-2-phenylacetamide
• CAS Number: 289656-45-7
• Molecular Formula: C20H15F2NO
• Molecular Weight: 323.336
• MDL Number: MFCD09027349
• SMILES: Fc1ccc(cc1)C(c1ccc(cc1)F)(c1ccccc1)C(=O)N

Computed Properties

• Complexity: 397
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 24
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 4.1

Literature

• Drugs for preventing red blood cell dehydration in people with sickle cell disease.

  The Cochrane database of systematic reviews 20120711

• Expression and Role of the Intermediate-Conductance Calcium-Activated Potassium Channel KCa3.1 in Glioblastoma.

  Journal of signal transduction 20120101

• Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease.

  International journal of Alzheimer's disease 20120101

• Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia.

  British journal of haematology 20111201

• Senicapoc trial results support the existence of different sub-phenotypes of sickle cell disease with possible drug-induced phenotypic shifts.

  British journal of haematology 20111201

• Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).

  British journal of haematology 20110401

• Drugs for preventing red blood cell dehydration in people with sickle cell disease.

  The Cochrane database of systematic reviews 20100120

• Hypoxia activates a Ca2+-permeable cation conductance sensitive to carbon monoxide and to GsMTx-4 in human and mouse sickle erythrocytes.

  PloS one 20100101

• Promising therapies in sickle cell disease.

  Cardiovascular & hematological disorders drug targets 20090301

• Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.

  Expert opinion on investigational drugs 20090201

• Pathophisiology of sickle cell disease and new drugs for the treatment.

  Mediterranean journal of hematology and infectious diseases 20090101

• Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.

  Blood 20080415

• Gardos pathway to sickle cell therapies?

  Blood 20080415

• Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.

  Journal of medicinal chemistry 20080227

• Dose-escalation study of ICA-17043 in patients with sickle cell disease.

  Pharmacotherapy 20061101

• Investigational agents for sickle cell disease.

  Expert opinion on investigational drugs 20060801

• Current therapy of sickle cell disease.

  Haematologica 20060101

• [Clinical trials of new therapeutic pharmacology for sickle cell disease].

  Sante (Montrouge, France) 20060101

• New therapies for sickle cell disease.

  Hematology/oncology clinics of North America 20051001

• ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice.

  Blood 20030315